p.105 抽出テキスト

Circulation 2018;137:88–90. https://doi.org/10.1161/CIRCULATIONAHA. 117.030924 843. Shen L, Rorth R, Cosmi D, Kristensen SL, Petrie MC, Cosmi F, et al. Insulin treatment and clinical outcomes in patients with diabetes and heart failure with preserved ejection fraction. Eur J Heart Fail 2019;21:974–84. https:// doi.org/10.1002/ejhf.1535 844. Cosmi F, Shen L, Magnoli M, Abraham WT, Anand IS, Cleland JG, et al. Treatment with insulin is associated with worse outcome in patients with chronic heart failure and diabetes. Eur J Heart Fail 2018;20:888–95. https://doi.org/10.1002/ejhf.1146 845. Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 2013;369:1317–26. https://doi.org/10.1056/ NEJMoa1307684 846. Lago RM, Singh PP, Nesto RW. Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials. Lancet 2007;370: 1129–36. https://doi.org/10.1016/S0140-6736(07)61514-1 847. Damman K, Testani JM. The kidney in heart failure: an update. Eur Heart J 2015;36:1437–44. https://doi.org/10.1093/eurheartj/ehv010 848. George LK, Koshy SKG, Molnar MZ, Thomas F, Lu JL, Kalantar-Zadeh K, et al. Heart failure increases the risk of adverse renal outcomes in patients with normal kidney function. Circ Heart Fail 2017;10:e003825. https://doi.org/ 10.1161/CIRCHEARTFAILURE.116.003825 849. Iorio A, Senni M, Barbati G, Greene SJ, Poli S, Zambon E, et al. Prevalence and prognostic impact of non-cardiac co-morbidities in heart failure outpatients with preserved and reduced ejection fraction: a community-based study. Eur J Heart Fail 2018;20:1257–66. https://doi.org/10.1002/ejhf.1202 850. Damman K, Valente MA, Voors AA, O’Connor CM, van Veldhuisen DJ, Hillege HL. Renal impairment, worsening renal function, and outcome in patients with heart failure: an updated meta-analysis. Eur Heart J 2014;35: 455–69. https://doi.org/10.1093/eurheartj/eht386 851. Chatur S, Vaduganathan M, Peikert A, Claggett BL, McCausland FR, Skali H, et al. Longitudinal trajectories in renal function before and after heart failure hospitalization among patients with heart failure with preserved ejection fraction in the PARAGON-HF trial. Eur J Heart Fail 2022;24:1906–14. https://doi.org/10.1002/ejhf.2638 852. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004;351:1296–305. https://doi.org/10.1056/NEJMoa041031 853. Khayyat-Kholghi M, Oparil S, Davis BR, Tereshchenko LG. Worsening kidney function is the major mechanism of heart failure in hypertension: the ALLHAT study. JACC Heart Fail 2021;9:100–11. https://doi.org/10.1016/j. jchf.2020.09.006 854. Kottgen A, Russell SD, Loehr LR, Crainiceanu CM, Rosamond WD, Chang PP, et al. Reduced kidney function as a risk factor for incident heart failure: the atherosclerosis risk in communities (ARIC) study. J Am Soc Nephrol 2007; 18:1307–15. https://doi.org/10.1681/ASN.2006101159 855. Savarese G, Lindberg F, Cannata A, Chioncel O, Stolfo D, Musella F, et al. How to tackle therapeutic inertia in heart failure with reduced ejection fraction. A scientific statement of the Heart Failure Association of the ESC. Eur J Heart Fail 2024;26:1278–97. https://doi.org/10.1002/ejhf.3295 856. Damman K, Tang WH, Felker GM, Lassus J, Zannad F, Krum H, et al. Current evidence on treatment of patients with chronic systolic heart failure and renal insufficiency: practical considerations from published data. J Am Coll Cardiol 2014;63:853–71. https://doi.org/10.1016/j.jacc.2013.11.031 857. Butler J, Packer M, Siddiqi TJ, Bohm M, Brueckmann M, Januzzi JL, et al. Efficacy of empagliflozin in patients with heart failure across kidney risk categories. J Am Coll Cardiol 2023;81:1902–14. https://doi.org/10.1016/j.jacc. 2023.03.390 858. Kotecha D, Gill SK, Flather MD, Holmes J, Packer M, Rosano G, et al. Impact of renal impairment on beta-blocker efficacy in patients with heart failure. J Am Coll Cardiol 2019;74:2893–904. https://doi.org/10.1016/j.jacc.2019.09. 059 859. Chatur S, Vaduganathan M, Claggett BL, McCausland FR, Desai AS, Jhund PS, et al. Dapagliflozin in patients with heart failure and deterioration in renal function. J Am Coll Cardiol 2023;82:1854–63. https://doi.org/10.1016/j. jacc.2023.08.026 860. McCausland FR, Vaduganathan M, Claggett BL, Kulac IJ, Desai AS, Jhund PS, et al. Finerenone and kidney outcomes in patients with heart failure: the FINEARTS-HF trial. J Am Coll Cardiol 2025;85:159–68. https://doi.org/10. 1016/j.jacc.2024.10.091 861. Borlaug BA, Zile MR, Kramer CM, Baum SJ, Hurt K, Litwin SE, et al. Effects of tirzepatide on circulatory overload and end-organ damage in heart failure with preserved ejection fraction and obesity: a secondary analysis of the SUMMIT trial. Nat Med 2025;31:544–51. https://doi.org/10.1038/ s41591-024-03374-z 862. Perkovic V, Tuttle KR, Rossing P, Mahaffey KW, Mann JFE, Bakris G, et al. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes. N Engl J Med 2024;391:109–21. https://doi.org/10.1056/ NEJMoa2403347 863. Metra M, Cotter G, Gheorghiade M, Dei Cas L, Voors AA. The role of the kidney in heart failure. Eur Heart J 2012;33:2135–42. https://doi.org/10.1093/ eurheartj/ehs205 864. Ter Maaten JM, Mebazaa A, Davison B, Edwards C, Adamo M, Arrigo M, et al. Early changes in renal function during rapid up-titration of guideline-directed medical therapy following an admission for acute heart failure. Eur J Heart Fail 2023;25:2230–42. https://doi.org/10.1002/ejhf.3074 865. Lindberg F, Lund LH, Benson L, Linde C, Orsini N, Carrero JJ, et al. Iron deficiency in heart failure: screening, prevalence, incidence and outcome data from the Swedish Heart Failure Registry and the Stockholm CREAtinine Measurements collaborative project. Eur J Heart Fail 2023;25:1270–80. https://doi.org/10.1002/ejhf.2879 866. Savarese G, von Haehling S, Butler J, Cleland JGF, Ponikowski P, Anker SD. Iron deficiency and cardiovascular disease. Eur Heart J 2023;44:14–27. https://doi.org/10.1093/eurheartj/ehac569 867. Anand IS, Gupta P. Anemia and iron deficiency in heart failure: current concepts and emerging therapies. Circulation 2018;138:80–98. https://doi.org/ 10.1161/CIRCULATIONAHA.118.030099 868. von Haehling S, Jankowska EA, van Veldhuisen DJ, Ponikowski P, Anker SD. Iron deficiency and cardiovascular disease. Nat Rev Cardiol 2015;12:659–69. https://doi.org/10.1038/nrcardio.2015.109 869. Masini G, Graham FJ, Pellicori P, Cleland JGF, Cuthbert JJ, Kazmi S, et al. Criteria for iron deficiency in patients with heart failure. J Am Coll Cardiol 2022;79:341–51. https://doi.org/10.1016/j.jacc.2021.11.039 870. Packer M, Anker SD, Butler J, Cleland JGF, Kalra PR, Mentz RJ, et al. Redefining iron deficiency in patients with chronic heart failure. Circulation 2024;150:151–61. https://doi.org/10.1161/CIRCULATIONAHA.124. 068883 871. Beavers CJ, Ambrosy AP, Butler J, Davidson BT, Gale SE, Pina IL, et al. Iron deficiency in heart failure: a scientific statement from the Heart Failure Society of America. J Card Fail 2023;29:1059–77. https://doi.org/10.1016/ j.cardfail.2023.03.025 872. Anker SD, Khan MS, Butler J, von Haehling S, Jankowska EA, Ponikowski P, et al. Effect of intravenous iron replacement on recurrent heart failure hospitalizations and cardiovascular mortality in patients with heart failure and iron deficiency: a Bayesian meta-analysis. Eur J Heart Fail 2023;25:1080–90. https://doi.org/10.1002/ejhf.2860 873. Martens P, Augusto SN Jr, Mullens W, Tang WHW. Meta-analysis and metaregression of the treatment effect of intravenous iron in iron-deficient heart failure. JACC Heart Fail 2024;12:525–36. https://doi.org/10.1016/j.jchf. 2023.11.006 874. Ponikowski P, Mentz RJ, Hernandez AF, Butler J, Khan MS, van Veldhuisen DJ, et al. Efficacy of ferric carboxymaltose in heart failure with iron deficiency: an individual patient data meta-analysis. Eur Heart J 2023;44: 5077–91. https://doi.org/10.1093/eurheartj/ehad586 875. Ponikowski P, van Veldhuisen DJ, Comin-Colet J, Ertl G, Komajda M, Mareev V, et al. Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency. Eur Heart J 2015;36:657–68. https://doi.org/10.1093/eurheartj/ ehu385 876. Anker SD, Comin-Colet J, Filippatos G, Willenheimer R, Dickstein K, Drexler H, et al. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med 2009;361:2436–48. https://doi.org/10.1056/ NEJMoa0908355 877. Comin-Colet J, Lainscak M, Dickstein K, Filippatos GS, Johnson P, Luscher TF, et al. The effect of intravenous ferric carboxymaltose on health-related quality of life in patients with chronic heart failure and iron deficiency: a subanalysis of the FAIR-HF study. Eur Heart J 2013;34:30–38. https://doi.org/10. 1093/eurheartj/ehr504 878. van Veldhuisen DJ, Ponikowski P, van der Meer P, Metra M, Bohm M, Doletsky A, et al. Effect of ferric carboxymaltose on exercise capacity in patients with chronic heart failure and iron deficiency. Circulation 2017;136: 1374–83. https://doi.org/10.1161/CIRCULATIONAHA.117.027497 879. Kalra PR, Cleland JGF, Petrie MC, Thomson EA, Kalra PA, Squire IB, et al. Intravenous ferric derisomaltose in patients with heart failure and iron deficiency in the UK (IRONMAN): an investigator-initiated, prospective, randomised, open-label, blinded-endpoint trial. Lancet 2022;400:2199–209. https://doi.org/10.1016/S0140-6736(22)02083-9 880. von Haehling S, Doehner W, Evertz R, Garfias-Veitl T, Derad C, Diek M, et al. Ferric carboxymaltose and exercise capacity in heart failure with preserved Downloaded from academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehag100/8766302 by guest on 31 August 2026